Advertisement for orthosearch.org.uk
Results 1 - 20 of 55
Results per page:
Bone & Joint 360
Vol. 13, Issue 5 | Pages 5 - 6
1 Oct 2024
Ollivere B


Bone & Joint Open
Vol. 5, Issue 9 | Pages 806 - 808
27 Sep 2024
Altorfer FCS Lebl DR


The Bone & Joint Journal
Vol. 106-B, Issue 9 | Pages 884 - 886
1 Sep 2024
Brown R Bendall S Aronow M Ramasamy A


The Bone & Joint Journal
Vol. 106-B, Issue 7 | Pages 642 - 645
1 Jul 2024
Harris IA Sidhu VS MacDessi SJ Solomon M Haddad FS


The Bone & Joint Journal
Vol. 106-B, Issue 6 | Pages 516 - 521
1 Jun 2024
Al-Hourani K Haddad FS


The Bone & Joint Journal
Vol. 106-B, Issue 6 | Pages 522 - 524
1 Jun 2024
Kennedy JW Jones JD Meek RMD


The Bone & Joint Journal
Vol. 106-B, Issue 4 | Pages 303 - 306
1 Apr 2024
Staats K Kayani B Haddad FS


Bone & Joint 360
Vol. 13, Issue 1 | Pages 5 - 5
1 Feb 2024
Ollivere B


The Bone & Joint Journal
Vol. 106-B, Issue 2 | Pages 111 - 113
1 Feb 2024
Howard A Thomas GER Perry DC


The Bone & Joint Journal
Vol. 105-B, Issue 8 | Pages 837 - 838
1 Aug 2023
Kelly M McNally SA Dhesi JK


Bone & Joint Research
Vol. 12, Issue 1 | Pages 5 - 8
1 Jan 2023
Im G

Cite this article: Bone Joint Res 2023;12(1):5–8.


Bone & Joint 360
Vol. 11, Issue 6 | Pages 3 - 4
1 Dec 2022
Ollivere B


Bone & Joint 360
Vol. 11, Issue 5 | Pages 3 - 4
1 Oct 2022
Ollivere B


Bone & Joint 360
Vol. 11, Issue 4 | Pages 3 - 3
1 Aug 2022
Ollivere B


Bone & Joint Research
Vol. 11, Issue 4 | Pages 210 - 213
1 Apr 2022
Fontalis A Haddad FS


The Bone & Joint Journal
Vol. 103-B, Issue 8 | Pages 1326 - 1327
1 Aug 2021
Craven J Haddad FS Perry DC



Bone & Joint Research
Vol. 10, Issue 2 | Pages 134 - 136
1 Feb 2021
Im G

The high prevalence of osteoarthritis (OA), as well as the current lack of disease-modifying drugs for OA, has provided a rationale for regenerative medicine as a possible treatment modality for OA treatment. In this editorial, the current status of regenerative medicine in OA including stem cells, exosomes, and genes is summarized along with the author’s perspectives. Despite a tremendous interest, so far there is very little evidence proving the efficacy of this modality for clinical application. As symptomatic relief is not sufficient to justify the high cost associated with regenerative medicine, definitive structural improvement that would last for years or decades and obviate or delay the need for joint arthroplasty is essential for regenerative medicine to retain a place among OA treatment methods.

Cite this article: Bone Joint Res 2021;10(2):134–136.


The Bone & Joint Journal
Vol. 102-B, Issue 10 | Pages 1277 - 1278
1 Oct 2020
Hughes R Hallstrom B Schemanske C Howard PW Wilton T


The Bone & Joint Journal
Vol. 102-B, Issue 9 | Pages 1111 - 1112
14 Sep 2020
Perry DC Costa M